InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-12-11 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-04-17 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-01-29 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2024-01-24 | Josh Gottheimer(D-NJ05) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total product revenue, net | $54.0M+48.0% | $36.5M+36.1% | $26.8M | — | — |
| Cost of sales | $6.3M+52.3% | $4.2M+44.6% | $2.9M+69.1% | $1.7M | $0 |
| Research and development | $339.5M+12.7% | $301.3M+1.9% | $295.5M+5.6% | $279.9M+8.9% | $257.0M |
| Total selling, general and administrative expenses | $180.3M+15.0% | $156.8M+30.8% | $119.9M | — | — |
| Total operating expenses | $526.2M+13.8% | $462.2M+10.5% | $418.3M+3.7% | $403.3M+6.6% | $378.4M |
| Loss from operations | -$472.1M-10.9% | -$425.7M-8.7% | -$391.5M-0.6% | -$389.0M-2.8% | -$378.4M |
| Gain on sale of contingent payments | $0-100.0% | $889.1M | $0-100.0% | $127.9M | $0 |
| Milestone payment from gain on sale of oncology business | $0-100.0% | $200.0M | $0 | $0 | — |
| Interest income, net | $56.4M+17.3% | $48.1M+44.2% | $33.3M+160.6% | $12.8M+1430.3% | $836K |
| Other income, net | $2.0M-69.8% | $6.5M+7.1% | $6.1M-10.3% | $6.7M-53.2% | $14.4M |
| Net (loss) income before taxes | -$413.8M-157.6% | $718.0M+303.9% | -$352.1M | — | — |
| Income tax (benefit) expense | -$1.0M-102.3% | $44.2M | $0 | — | — |
| Net (loss) income | -$412.8M-161.3% | $673.7M+291.4% | -$352.1M | — | $1.60B |
| Net income (loss) per share - basic (in usd per share) | -$7K-160.0% | $12K+287.4% | -$6K-49.6% | -$4K | — |
| Net income (loss) per share - diluted (in usd share) | -$7K-161.2% | $12K+283.9% | -$6K-49.6% | -$4K | — |
| Weighted-average number of common shares used in computing net income (loss) per share – basic (in shares) | $57.97B+2.1% | $56.81B+2.1% | $55.65B+1.6% | $54.79B | — |
| Weighted-average number of common shares used in computing net income (loss) per share – diluted (in shares) | $57.97B+0.1% | $57.89B+4.0% | $55.65B+1.6% | $54.79B | — |
| Product revenue, net | |||||
| Total product revenue, net | $54.0M+48.0% | $36.5M+36.1% | $26.8M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Agios Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation